Application note: Middle-up mass analysis of protease digested cetuximab
Posted: 30 November 2022 | Merck | No comments yet
Protocol for purification, proteolysis, reduction and UHPLC-MS analysis of unlabelled and labelled monoclonal antibodies
This application note details a complete workflow of a middle-up mass analysis of protease digested Cetuximab monoclonal antibody, starting with the antibody purification, proteolysis and reduction to its reversed phase UHPLC-MS analysis.
Related content from this organisation
- Moderna-Merck & Co cancer vaccine with Keytruda shows late-stage promise
- Raman-based PAT tool could advance continuous vaccine manufacturing
- Merck acquires JSR Life Sciences chromatography business
- MSD acquisition to accelerate first-in-class COPD drug
- Next drug patent cliff to challenge Big Pharma strategy
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Research & Development (R&D)
